FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      
           
This page is updated frequently with new Factor-related patent applications. Subscribe to the Factor RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor RSS RSS


Tuning device for pluggable optical transceivers

Champion Optical Network Engineering

Tuning device for pluggable optical transceivers

Date/App# patent app List of recent Factor-related patents
03/26/15
20150089288
 Technique for establishing an audio socket debug connection patent thumbnailnew patent Technique for establishing an audio socket debug connection
A debug controller monitors a tip-ring-ring-shield (trrs) socket, within a form factor device, to detect whether a debug unit is transmitting a request for a trrs socket debug connection. The form factor device also includes a system on chip (soc), a switch, and an audio codec.
Nvidia Corporation
03/26/15
20150088620
 System and  reminding and tracking use of reusable container and carry products patent thumbnailnew patent System and reminding and tracking use of reusable container and carry products
The present disclosure relates to a system and method for reminding users to use, and for tracking usage of, reusable container and carry products such as reusable bags, boxes, cups, cup sleeves, and bottles, especially for food and beverages. In an aspect, the system and method provides an identification module which may be attached to or embedded within a reusable container or carry product.
03/26/15
20150088222
 Ingestible, electrical device for stimulating tissues in a gastrointestinal tract of an organism patent thumbnailnew patent Ingestible, electrical device for stimulating tissues in a gastrointestinal tract of an organism
In one aspect, an ingestible, electrical device, comprises one or more electrodes comprising a biocompatible conducting material and a biocompatible insulating material; a generator connected to the one or more electrodes; and an outer casing enclosing the one or more electrodes and the generator, the outer casing configured to dissolve in an aqueous environment of the organism; wherein the one or more electrodes have a first form factor when enclosed in the outer casing and a second form factor following a dissolution of the outer casing, the first form factor is a form factor that is collapsed an increased amount relative to an amount that the second form factor is collapsed, and the second form factor is a form factor that is collapsed a decreased amount relative to an amount that the first form factor is collapsed.. .
Carnegie Mellon University
03/26/15
20150087597
 Polypeptides and methods of use patent thumbnailnew patent Polypeptides and methods of use
Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin.
The Research Foundation For The State University Of New York
03/26/15
20150087593
 Coagulation factor viii with reduced immunogenicity patent thumbnailnew patent Coagulation factor viii with reduced immunogenicity
B. Modification of said epitope(s) by eliminating at least one hydrophobic aminoacid residues in position p1 and/or p7, substituting at least one hydrophobic aminoacid residue in position p1 and/or p7 with a non-hydrophobic residue, or adding a non-hydrophobic residue in position p1 and/or p7..
03/26/15
20150087062
 System and  electrospun biodegradable scaffold for bone repair patent thumbnailnew patent System and electrospun biodegradable scaffold for bone repair
This invention relates a structure and system for growth factor incorporation which can improve the osteogenic differentiation of hmscs, for potential bone regeneration and bone growth applications or used alone for bone repair or growth applications. The system comprises a biodegradable polyester, a hydrophilic polymer, a growth factor and optionally a bioceramic..
03/26/15
20150087060
 Method for inducing erythropoietin-producing cell patent thumbnailnew patent Method for inducing erythropoietin-producing cell
An object of the present invention is to provide a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells. The above object is achieved by providing a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells using a medium containing a specific growth factor and a specific compound..
Kyoto University
03/26/15
20150087058
 Stem cell culture medium and  culturing stem cells using same patent thumbnailnew patent Stem cell culture medium and culturing stem cells using same
The present invention relates to a stem cell culture medium which can be substituted for a conventional stem cell culture medium containing the heterologous protein fetal bovine serum, and more particularly to a stem cell culture medium containing a basal medium and a knockout serum replacement and a method of culturing stem cells using the same. According to the invention, a high purity of stem cells having a reduced ability to spontaneously differentiate can be obtained without having to use the heterologous protein fetal bovine serum and expensive growth factors (egf and bfgf), and thus the efficacy of stem cell therapy can be significantly increased..
Samsung Life Public Welfare Foundation
03/26/15
20150086616
 Method for the prevention and treatment of alzheimer's disease patent thumbnailnew patent Method for the prevention and treatment of alzheimer's disease
Oral non-steroidal anti inflammatory drugs (nsaids) are not an effective treatment of alzheimer's disease, because the brain dose is too low. Nasal delivery of nsaids such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat alzheimer's disease, a low grade brain inflammation.
03/26/15
20150086547
 Combination therapy for treating breast cancer patent thumbnailnew patent Combination therapy for treating breast cancer
The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a transforming growth factor beta (tgfβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer..
Genzyme Corporation
03/26/15
20150086214
new patent

Tuning device for pluggable optical transceivers


A tuning device for a pluggable xfp and sfp+ and dwdm transceiver devices. Also provided are applications for cwdm xfp, and sfp+ and future form factors as well as dwdm and cwdm sfp.
Champion Optical Network Engineering, Llc
03/26/15
20150086175
new patent

Integrated video and audio recording and transmission


A device includes a body-worn camera and small form factor digital video recorder that is integrated with a wireless microphone and transmitter that interoperates with an in-car video system.. .
Mobile-vision, Inc.
03/19/15
20150082281

System and providing access to data in a plurality of software development systems


Systems and method are provided for determining risk of product release failure in an environment where multiple independent releases come together into a shared environment. A risk factor for success or failure of a product release is based on release information input by a user and information input by other users regarding releases, the users typically on distinct development systems.
Fmr Llc
03/19/15
20150080785

Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis


This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies etanercept, igf-1, and acetylcholine esterase inhibitors physostigmine, for treatment of alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, etanercept, igf-1, and physostigmine therapeutic agents.
Wedge Therapeutics, Llc
03/19/15
20150080475

Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia


This invention relates to a method of treating opiate addiction caused by microglial over-activation-mediated dopamine (da) neurons damage, comprising administering a human in need of such treatment 0.01-0.08 mg/kg of 1-amino-3,5-dimethyladamantane hydrochloride orally per day.. .
03/19/15
20150080455

Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3


The present invention relate to antisense oligonucleotides that modulate the expression of and/or function of transcription factor e3 (tfe3) and/or insulin receptor substrate 2 (irs2) polynucleotides, in particular, by targeting natural antisense polynucleotides of transcription factor e3 (tfe3) and/or insulin receptor substrate 2 (irs2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of tfe3 and/or irs2..
Curna, Inc.
03/19/15
20150080306

Therapeutic agents comprising elastic peptides


The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation.
Duke University
03/19/15
20150080304

Treatment and prevention of radiation injury using mfg-e8


Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor viii (mfg-e8).. .
The Feinstein Institute For Medical Research
03/19/15
20150080300

Growth factor concentrate and the use thereof


Provided herein are growth factor concentrates, cosmetic compositions and methods for cosmetic treatment. The growth factor concentrates comprise decapsulated growth factors derived from platelet rich plasma..
Bestop Group Holdings Limited
03/19/15
20150079194

Systems, compositions, and methods for transplantation and treating conditions


Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation
03/19/15
20150079153

Cell suspension and use thereof


The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between.
Avita Medical Ltd.
03/19/15
20150079101

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/19/15
20150079087

Vegf antagonist formulations


Formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of seq id no:4..
Regeneron Pharmaceuticals, Inc.
03/19/15
20150079084

Protein inhibitors to complement and vegf pathways and methods of use thereof


The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (vegf) pathway and methods for using these fusion proteins.. .
Innovent Biologies, Inc.
03/19/15
20150079080

Novel anti-igf-ir antibodies and uses thereof


The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor i receptor igf-ir and/or capable of specifically inhibiting the tyrosine kinase activity of said igf-ir receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing igf-ir or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the igf-ir receptor.
Merck Sharp & Dohme Corp.; Institute De Recherche Pierre Fabre
03/19/15
20150079072

Assays to monitor bleeding disorders


The present invention provides methods of dosing factor viii or factor ix chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated fix protein in a test sample.
Biogen Idec Hemophilia Inc.
03/19/15
20150079048

Method for in vivo, ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling


A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure.
The Board Of Trustees Of The Leland Stanford Junior University
03/19/15
20150078996

Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders


The present invention relates to mammalian antibodies, designated 12b1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor i receptor (igf-ir), preferably human igf-ir. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein.
Pierre Fabre Medicament
03/19/15
20150078005

Solid-state lighting devices and systems


A solid-state lighting device for use in lieu of a gas discharge lamp, includes a housing; a lens coupled to the housing; a circuit board; and a plurality of solid-state light emitters carried by the circuit board and arranged to generate light to pass through the lens. An entirety of a form factor of the solid-state lighting device may be located within a cylindrical envelope having a length less than or about equal to an overall length of the gas discharge lamp and a diameter less than or about equal to the overall diameter of the gas discharge lamp.
Express Imaging Systems, Llc
03/19/15
20150077877

Enlarged substrate for magnetic recording medium


An enlarged substrate for a magnetic recording medium used in a data storage device such as a hard disc drive (hdd). In some embodiments, an apparatus includes a substrate for a magnetic recording disc for installation in a 3½ inch form factor hard disc drive, the substrate having an overall diameter of nominally from 96.9 mm to 100.4 mm.
Seagate Technology Llc
03/19/15
20150077292

Deposited three-dimensional antenna apparatus and methods


A “thin” and cost-effective three-dimensional antenna assembly and methods of use and manufacturing thereof. In one exemplary embodiment, the solution of the present disclosure is particularly adapted for small form-factor portable radio devices, and comprises an antenna (or array of antennas) deposited on a thin preformed flexible or deformable structure using a conductive fluid.
Pulse Finland Oy
03/19/15
20150076912

Auto-switching duplex module


A system and method (“utility”) for providing power to an electrically powered device from alternate, redundant power sources via a single power cord. The utility is operable to provide redundant power to an electrical device having a power cord terminating in a standard plug.
Zonit Structured Solutions, Llc
03/19/15
20150076189

Housing for an electronic device


This disclosure relates generally to an apparatus for housing electronic devices. It introduces a modular form factor for utilizing tablet computers as components within fixed computer terminals.
03/12/15
20150074853

Methods for increasing cotton fiber length


The present invention relates to the field of plant molecular biology, more particularly cotton wrinkled 1-like (wrel) genes. More specifically, the present invention relates to cotton wril genes whose products act as transcription factors of genes involved in fatty acid biosynthesis.
Temasek Life Sciences Laboratory Limited
03/12/15
20150074846

Methods and compositions for modifying plant flavonoid composition and disease resistance


The invention provides methods, compositions and transformation systems for modifying the levels of transcription factors in plants such as solanaceous plants, and introducing disease resistance genes into plants, to produce products with elevated levels of antioxidant compounds, including but not limited to flavonols and chlorogenic acid, as well as exhibiting enhanced disease resistance, and optionally altered appearance. Preferred plants are those in which introduced genes are from solanaceous species..
Norfolk Plant Sciences Limited
03/12/15
20150074014

System and automated role re-factoring


In an example embodiment, roles within a job based security model are refactored to roles within a task oriented security model. The task oriented security model comprises task roles, which allow access to functionality and data, and enabler roles, which provide limits on the scope of the task roles.
Sap Ag
03/12/15
20150073862

System and risk optimized, spatially sensitive preventive maintenance scheduling for asset management


A preventative maintenance method and a system for estimating the risk of failure of an asset based on intrinsic parameters such as failure history combined with causative factors like weather and independent external risk factors such as vandalism and risk of flooding. The present invention may further have a system for estimating the risk of failure of an asset based on intrinsic parameters, such as failure history combined with causative factors such as weather and independent external risk factors like vandalism and risk of flooding having a location based asset/service failure risk estimator, an external risk estimates database for feeding and an integrated failure risk database, the external risk estimates database feeding the integrated failure risk database..
International Business Machines Corporation
03/12/15
20150073835

System and generating an insurance quote of a property in real-time


The present subject matter described herein, in general, relates to insurance, and more particularly to a system and method for generating an insurance quote of a property in real-time. In one embodiment, a real-time insurance quote generation method is disclosed, comprising: obtaining a user selection, via a single action, of a property displayed on a map via a user interface of a device; determining an address of the property using at least geo co-ordinate details; collating data associated with the property from a plurality of data sources; assessing one or more risk factors associated with the property and underwriting the property based upon the data; computing, via a processor, an insurance quote for the property by using at least one of the data or the one or more risk factors; and providing the insurance quote..
Tata Consultancy Services Limited
03/12/15
20150073330

Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis


This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies etanercept, igf-1, and acetylcholine esterase inhibitors physostigmine, for treatment of alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, etanercept, igf-1, and physostigmine therapeutic agents.
Wedge Therapeutics, Llc
03/12/15
20150073025

Method for identifying disease risk factors


Provided herein is a method for identifying a genetic variant that is associated with development of a condition of interest (e.g., alzheimer's disease), and genetic variants so identified. Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein.
Zinfandel Pharmaceuticals, Inc.
03/12/15
20150073022

Disease risk factors and methods of use


Provided herein are genetic variants associated with development of a condition of interest (e.g., alzheimer's disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein.
Zinfandel Pharmaceuticals, Inc.
03/12/15
20150072986

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
03/12/15
20150072434

Methods for assessing risk of bone fracture


The invention generally relates to methods for assessing risk of bone fracture. In certain embodiments, methods of the invention involve a) conducting an assay to determine a characteristic of keratinized tissue obtained from a mammal, b) analyzing at least one bone-fracture risk factor associated with the mammal, and c) correlating results from steps (a) and (b), thereby assessing the risk of bone fracture of a bone of the mammal..
Crescent Diagnostics Limited
03/12/15
20150072431

Mature dendritic cell compositions and methods for culturing same


This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.
03/12/15
20150072426

Fgf-2 variants and methods of use thereof


A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal fgf receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (fgf-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said fgf-9 variant incorporates one of the amino acid sequences set forth in seq id no: 11, 13, 14, 15, 16 or 17..
Prochon Biotech Ltd.
03/12/15
20150072032

Extract of adlay bran and uses thereof


The present invention provides a composition comprising extract of adlay bran, wherein the adlay bran extract comprises c1 to c7 alcohol extract of adlay bran (a) and carbon dioxide supercritical fluid extract of adlay bran (b). Preferably, the extract of adlay bran has effects in treating a skin and/or subcutaneous tissue disease and in lowering interleukin (il)-1α, interleukin-1⊖, interleukin-6, tumor necrosis factor (tnf)-α, interleukin-8, prostaglandin-2 (pge2) and/or c-reactive protein (crp)..
Joben Bio-medical Co., Ltd.
03/12/15
20150072007

Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof


The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ.
Immunopath Profile, Inc.
03/12/15
20150071945

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/12/15
20150071939

Methods of administering anti-tnfalpha antibodies


Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd.
03/12/15
20150071923

Modified anti-epidermal growth factor receptor antibodies and methods of use thereof


Provided herein are modified anti-egfr antibodies and nucleic acid molecules encoding modified anti-egfr antibodies. Also provided are methods of treatment and uses using modified anti-egfr antibodies..
03/12/15
20150071883

Adeno-associated virus factor viii vectors


The invention provides improved adeno-associated virus (aav) factor viii (fviii) vectors, including aav fviii vectors that produce a functional factor viii polypeptide and aav fviii vectors with high expression activity.. .
Biomarin Pharmaceutical Inc.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.542

3708

0 - 1 - 75